Climb Bio, Inc. Common Stock (CLYM)

• Market cap: $85.1M
• 1 day: -1.65%
• 5 days: -7.75%
• 1 month: 5.31%
• 3 months: -24.68%
• 6 months: -68.60%
• Year to date: -42.51%
• 1 year: -87.23%
• 5 years: -92.52%
• 10 years: -92.52%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Employees: 18

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

133% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 12

53% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 17

11% more funds holding

Funds holding: 71 [Q3] → 79 (+8) [Q4]

1.36% more ownership

Funds ownership: 81.52% [Q3] → 82.87% (+1.36%) [Q4]

64% less capital invested

Capital invested by funds: $278M [Q3] → $100M (-$178M) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]